Vaccination against influenza: Role and limitations in pandemic intervention plans

Expert Review of Vaccines

Volumn 11, Issue 8, 2012, Pages 1009-1019

  Rebmann, Terri ^a   Zelicoff, Alan ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

compliance; H1N1; H5N1; herd protection; pandemic; public health; surge capacity; vaccine

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE;

2009 H1N1 INFLUENZA; ASIAN INFLUENZA; HEALTH CARE POLICY; HEALTH EDUCATION; HONG KONG INFLUENZA; HUMAN; IMMUNITY; IMMUNOGENICITY; INFLUENZA; INFLUENZA A (H5N1); INFLUENZA VACCINATION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TREATMENT PLANNING; UNITED STATES;

ANTIGENIC VARIATION; DISEASE TRANSMISSION, INFECTIOUS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MASS VACCINATION; PANDEMICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REASSORTANT VIRUSES;

EID: 84866645376     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.63     Document Type: Review

References (86)

1. Wise HM, Foeglein A, Sun J et al. A complicated message: identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA. J. Virol. 83(16), 8021-8031 (2009).
2. Kilbourne ED. Influenza. Plenum, NY, USA (1987).
3. Tong S, Li Y, Rivailler P et al. A distinct lineage of influenza A virus from bats. Proc. Natl Acad. Sci. USA 109(11), 4269-4274 (2012).
4. Ito T, Kawaoka Y. Host-range barrier of influenza A viruses. Veterinary Microbiol. 74(1-2), 71-75 (2000).
5. Hay AJ, Gregory V, Douglas AR, Lin YP. The evolution of human influenza viruses. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 356(1416), 1861-1870 (2001).
6. Hampson AW. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann. Acad. Med. Singap. 37(6), 510-517 (2008).
7. Belshe RB. The origins of pandemic influenza-lessons from the 1918 virus. N. Engl. J. Med. 353(21), 2209-2211 (2005).
8. Wertheim JO. The re-emergence of H1N1 influenza virus in 1977: a cautionary tale for estimating divergence times using biologically unrealistic sampling dates. PLoS ONE 5(6), e11184 (2010).
9. Shinde V, Bridges CB, Uyeki TM et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N. Engl. J. Med. 360(25), 2616-2625 (2009).
10. Kilbourne ED. Influenza pandemics of the 20th century. Emerg. Infect. Dis. 12(1), 9-14 (2006).
11. Taubenberger JK, Morens DM. 1918 influenza: the mother of all pandemics. Emerg. Infect. Dis. 12(1), 15-22 (2006).
12. Epstein SL. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J. Infect. Dis. 193(1), 49-53 (2006).
13. Dormitzer PR, Galli G, Castellino F et al. Influenza vaccine immunology. Immunol. Rev. 239(1), 167-177 (2011).
14. Falsey AR. New emerging technologies and the intradermal route: the novel way to immunize against influenza. Vaccine 28(Suppl. 4), D24-D32 (2010).
15. Kilbourne ED. Influenza immunity: new insights from old studies. J. Infect. Dis. 193(1), 7-8 (2006).
16. Rebmann T. Pandemic preparedness: implementation of infection prevention emergency plans. Infect. Control Hosp. Epidemiol. 31(Suppl. 1), S63-S65 (2010).
17. Rebmann T, Citarella B, Subramaniam DS, Subramaniam DP. A home health agency's pandemic preparedness and experience with the 2009 H1N1 pandemic. Am. J. Infect. Control 39(9), 725-731 (2011).
18. Milne G, Kelso J, Kelly H. Strategies for mitigating an influenza pandemic with pre-pandemic H5N1 vaccines. J. R. Soc. Interface 7(45), 573-586 (2010).
19. Bell DM; World Health Organization Writing Group. Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg. Infect. Dis. 12(1), 81-87 (2006).
20. Bell DM; World Health Organization Writing Group. Non-pharmaceutical interventions for pandemic influenza, national and community measures. Emerg. Infect. Dis. 12(1), 88-94 (2006).
21. de Jong MD, Tran TT, Truong HK et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353(25), 2667-2672 (2005).
22. Le QM, Kiso M, Someya K et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437(7062), 1108 (2005).
23. Lipsitch M, Cohen T, Murray M, Levin BR. Antiviral resistance and the control of pandemic influenza. PLoS Med. 4(1), e15 (2007).
24. Luke CJ, Subbarao K. Vaccines for pandemic influenza. Emerg. Infect. Dis. 12(1), 66-72 (2006).
25. Haaheim LR, Madhun AS, Cox R. Pandemic influenza vaccines-the challenges. Viruses 1(3), 1089-1109 (2009).
26. Lagacé-Wiens PR, Rubinstein E, Gumel A. Influenza epidemiology-past, present, and future. Crit. Care Med. 38(Suppl. 4), e1-e9 (2010).
27. Keeling MJ, White PJ. Targeting vaccination against novel infections: risk, age and spatial structure for pandemic influenza in Great Britain. J. R. Soc. Interface 8(58), 661-670 (2011).
28. Wu JT, Riley S, Leung GM. Spatial considerations for the allocation of pre-pandemic influenza vaccination in the United States. Proc. Biol. Sci. 274(1627), 2811-2817 (2007).
29. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12(1), 36-44 (2012).
30. Palese P. Making better influenza virus vaccines? Emerg. Infect. Dis. 12(1), 61-65 (2006).
31. Henderson DA, Courtney B, Inglesby TV, Toner E, Nuzzo JB. Public health and medical responses to the 1957-58 influenza pandemic. Biosecur. Bioterror. 7(3), 265-273 (2009).
32. Jensen KE, Dunn FL, Robinson RQ. Influenza, 1957: a variant and the pandemic. Prog. Med. Virol. 1, 165-209 (1958).
33. Eickhoff TC, Meiklejohn G. Protection against Hong Kong influneza by adjuvant vaccine containing A2-Ann Arbor-67. Bull. World Health Organ. 41(3), 562-563 (1969).
34. Igari H, Watanabe A, Chiba H et al. Effectiveness and safety of pandemic influenza A (H1N1) 2009 vaccine in healthcare workers at a university hospital in Japan. Jpn. J. Infect. Dis. 64(3), 177-182 (2011).
35. Puig-Barbera J, Arnedo-Pena A, Pardo-Serrano F et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based, case-control study. Vaccine 28(47), 7460-7467 (2010).
36. Carman WF, Elder AG, Wallace LA et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 355(9198), 93-97 (2000).
37. Lemaitre M, Meret T, Rothan-Tondeur M et al. Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial. J. Am. Geriatr. Soc. 57(9), 1580-1586 (2009).
38. Potter J, Stott DJ, Roberts MA et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J. Infect. Dis. 175(1), 1-6 (1997).
39. Schwartz B, Wortley P. Mass vaccination for annual and pandemic influenza. Curr. Top. Microbiol. Immunol. 304, 131-152 (2006).
40. Salgado CD, Giannetta ET, Hayden FG, Farr BM. Preventing nosocomial influenza by improving the vaccine acceptance rate of clinicians. Infect. Control Hosp. Epidemiol. 25(11), 923-928 (2004).
41. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N. Engl. J. Med. 344(12), 889-896 (2001).
42. Park SW, Lee JH, Kim ES et al. Adverse events associated with the 2009 H1N1 influenza vaccination and the vaccination coverage rate in health care workers. Am. J. Infect. Control 39(1), 69-71 (2011).
43. Chor JS, Ngai KL, Goggins WB et al. Willingness of Hong Kong healthcare workers to accept pre-pandemic influenza vaccination at different WHO alert levels: two questionnaire surveys. BMJ 339, b3391 (2009).
44. Lau JT, Yeung NC, Choi KC, Cheng MY, Tsui HY, Griffiths S. Acceptability of A/H1N1 vaccination during pandemic phase of influenza A/H1N1 in Hong Kong: population based cross sectional survey. BMJ 339, b4164 (2009).
45. Savas E, Tanriverdi D. Knowledge, attitudes and anxiety towards influenza A/H1N1 vaccination of healthcare workers in Turkey. BMC Infect. Dis. 10, 281 (2010).
46. Rebmann T, Wright KS, Anthony J, Knaup RC, Peters EB. Seasonal influenza vaccine compliance among hospital-based and nonhospital-based healthcare workers. Infect. Control Hosp. Epidemiol. 33(3), 243-249 (2012).
47. Meiklejohn GN. Asian influenza vaccination: dosage, routes, schedules of inoculation, and reactions. Am. Rev. Respir. Dis. 83 (2 Pt 2), 175-177 (1961).
48. Rockman S, Brown L. Pre-pandemic and pandemic influenza vaccines. Hum. Vaccin. 6(10), 792-801 (2010).
49. Hessel L; European Vaccine Manufacturers (EVM) Influenza Working Group. Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges. Influenza Other Respi. Viruses 3(4), 165-170 (2009).
50. Stöhr K. Vaccinate before the next pandemic? Nature 465(7295), 161 (2010).
51. Nabel GJ, Wei CJ, Ledgerwood JE. Vaccinate for the next H2N2 pandemic now. Nature 471(7337), 157-158 (2011).
52. Capua I, Kajaste-Rudnitski A, Bertoli E, Vicenzi E. Pandemic vaccine preparedness-have we left something behind? PLoS Pathog. 5(6), e1000482 (2009).
53. Kavet J. A perspective on the significance of pandemic influenza. Am. J. Public Health 67(11), 1063-1070 (1977).
54. Sencer DJ, Millar JD. Reflections on the 1976. swine flu vaccination program. Emerg. Infect. Dis. 12(1), 29-33 (2006).
55. Monto AS. Vaccines and antiviral drugs in pandemic preparedness. Emerg. Infect. Dis. 12(1), 55-60 (2006).
56. Riley S, Wu JT, Leung GM. Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate. PLoS Med. 4(6), e218 (2007).
57. Esposito S, Daleno C, Picciolli I et al. Immunogenicity and safety of intradermal influenza vaccine in children. Vaccine 29(44), 7606-7610 (2011).
58. Galvani AP, Medlock J, Chapman GB. The ethics of influenza vaccination. Science 313(5788), 758-760; author reply 758 (2006).
59. Vawter DE, Gervais KG, Garrett JE; Pandemic Influenza Ethics Work Group. Allocating pandemic influenza vaccines in Minnesota: recommendations of the Pandemic Influenza Ethics Work Group. Vaccine 25(35), 6522-6536 (2007).
60. Emanuel EJ, Wertheimer A. Public health. Who should get influenza vaccine when not all can? Science 312(5775), 854-855 (2006).
61. Harris K, Maurer J, Black C, Euler G, Kadiyala S. Workplace efforts to promote influenza vaccination among healthcare personnel and their association with uptake during the 2009 pandemic influenza A (H1N1). Vaccine 29(16), 2978-2985 (2011).
62. Qureshi K, Gershon RR, Sherman MF et al. Health care workers' ability and willingness to report to duty during catastrophic disasters. J. Urban Health 82(3), 378-388 (2005).
63. Syrett JI, Benitez JG, Livingston WH 3rd, Davis EA. Will emergency health care providers respond to mass casualty incidents? J. Healthc. Prot. Manage. 23(2), 27-40 (2007).
64. Rambhia KJ, Watson M, Sell TK, Waldhorn R, Toner E. Mass vaccination for the 2009 H1N1 pandemic: approaches, challenges, and recommendations. Biosecur. Bioterror. 8(4), 321-330 (2010).
65. Chamberlain AT, Seib K, Wells K et al. Perspectives of immunization program managers on 2009-10 H1N1 vaccination in the United States: a national survey. Biosecur. Bioterror. 10(1), 142-150 (2012).
66. Rinchiuso-Hasselmann A, McKay RL, Williams CA et al. Protecting the public from H1N1 through points of dispensing (PODs). Biosecur. Bioterror. 9(1), 13-21 (2011).
67. Sesardic D. Regulatory considerations on new adjuvants and delivery systems. Vaccine 24(Suppl. 2), S2-S86 (2006).
68. Quinn SC, Kumar S, Freimuth VS, Kidwell K, Musa D. Public willingness to take a vaccine or drug under Emergency Use Authorization during the 2009 H1N1 pandemic. Biosecur. Bioterror. 7(3), 275-290 (2009).
69. Paek HJ, Hilyard K, Freimuth VS, Barge JK, Mindlin M. Public support for government actions during a flu pandemic: lessons learned from a statewide survey. Health Promot. Pract. 9(Suppl. 4), 60S-72S (2008).
70. Hidiroglu S, Ay P, Topuzoglu A, Kalafat C, Karavus M. Resistance to vaccination: the attitudes and practices of primary healthcare workers confronting the H1N1 pandemic. Vaccine 28(51), 8120-8124 (2010).
71. Alkuwari MG, Aziz NA, Nazzal ZA, Al-Nuaimi SA. Pandemic influenza A/H1N1 vaccination uptake among health care workers in Qatar: motivators and barriers. Vaccine 29(11), 2206-2211 (2011).
72. Amodio E, Anastasi G, Marsala MG, Torregrossa MV, Romano N, Firenze A. Vaccination against the 2009 pandemic influenza A (H1N1) among healthcare workers in the major teaching hospital of Sicily (Italy). Vaccine 29(7), 1408-1412 (2011).
73. Del Campo MT, Miguel VJ, Susana C, Ana G, Gregoria L, Ignacio MF. 2009-2010. seasonal and pandemic A (H1N1) influenza vaccination among healthcare workers. Vaccine 29(20), 3703-3707 (2011).
74. Goldfield M, Bartley JD, Pizzuti W, Black HC, Altman R, Halperin WE. Influenza in New Jersey in 1976: isolations of influenza A/New Jersey/76 virus at Fort Dix. J. Infect. Dis. 136(Suppl.), S347-S355 (1977).
75. Maurer J, Uscher-Pines L, Harris KM. Perceived seriousness of seasonal and A(H1N1) influenzas, attitudes toward vaccination, and vaccine uptake among U.S. adults: does the source of information matter? Prev. Med. 51(2), 185-187 (2010).
76. Rebmann T, Iqbal A, Anthony J, Knaup RC, Wright KS, Peters EB. H1N1 influenza vaccine compliance among hospital-and non-hospital-based healthcare personnel. Infect. Control Hosp. Epidemiol. 33(7), 737-744 (2012).
77. Miyakis S, Giannakaki V, Moustakidis E et al. Vaccination against 2009 pandemic H1N1 influenza among healthcare workers in a tertiary hospital: rates, reasoning, beliefs. J. Hosp. Infect. 78(1), 75-76 (2011).
78. Seale H, Kaur R, Wang Q et al. Acceptance of a vaccine against pandemic influenza A (H1N1) virus amongst healthcare workers in Beijing, China. Vaccine 29(8), 1605-1610 (2011).
79. Babcock HM, Gemeinhart N, Jones M, Dunagan WC, Woeltje KF. Mandatory influenza vaccination of health care workers: translating policy to practice. Clin. Infect. Dis. 50(4), 459-464 (2010).
80. Rakita RM, Hagar BA, Crome P, Lammert JK. Mandatory influenza vaccination of healthcare workers: a 5-year study. Infect. Control Hosp. Epidemiol. 31(9), 881-888 (2010).
81. Ribner BS, Hall C, Steinberg JP et al. Use of a mandatory declination form in a program for influenza vaccination of healthcare workers. Infect. Control Hosp. Epidemiol. 29(4), 302-308 (2008).
82. Ajenjo MC, Woeltje KF, Babcock HM, Gemeinhart N, Jones M, Fraser VJ. Influenza vaccination among healthcare workers: ten-year experience of a large healthcare organization. Infect. Control Hosp. Epidemiol. 31(3), 233-240 (2010).
83. Talbot TR, Babcock H, Caplan AL et al. Revised SHEA position paper: influenza vaccination of healthcare personnel. Infect. Control Hosp. Epidemiol. 31(10), 987-995 (2010).
84. Walter D, Böhmer MM, Heiden M, Reiter S, Krause G, Wichmann O. Monitoring pandemic influenza A(H1N1) vaccination coverage in Germany 2009/10-results from thirteen consecutive cross-sectional surveys. Vaccine 29(23), 4008-4012 (2011).
85. Eastwood K, Durrheim DN, Jones A, Butler M. Acceptance of pandemic (H1N1) 2009. influenza vaccination by the Australian public. Med. J. Aust. 192(1), 33-36 (2010).
86. Uscher-Pines L, Maurer J, Harris KM. Racial and ethnic disparities in uptake and location of vaccination for 2009-H1N1 and seasonal influenza. Am. J. Public Health 101(7), 1252-1255 (2011).